Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 8/20 | 0.56 |
| ▸ | PI4KA | P42356 | 3/20 | 0.56 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.56 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.56 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.56 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.47 |
| ▸ | AHCY | P23526 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11862441 | 0.89 | ADORA2A (0.60) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL3395858 | 0.83 | HSP90AA1 (0.62) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL1422156 | 0.80 | NSD3 (0.70) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL11811272 | 0.78 | ADORA2A (0.64) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL6381371 | 0.77 | ADORA2A (0.63) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL288237 | 0.77 | ADORA2A (0.71) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL11827194 | 0.75 | HDAC6 (0.54) | HPGD | |
| SCHEMBL21788552 | 0.74 | ADORA2A (0.76) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL6659204 | 0.73 | ADORA2A (0.74) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| 9-Benzyl-9H-Adenine SCHEMBL104932 | 0.73 | ADORA2A (1.00) | ADORA2API4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10174033-B2 | N6-substituted adenosine derivatives and N6-substituted adenine derivatives and uses thereof | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2019-01-08 | — | — | US | disclosed |
| US-20130045942-A1 | N6-SUBSTITUTED ADENOSINE DERIVATIVES AND N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2013-02-21 | — | — | US | disclosed |
| EP-2511283-A1 | N6-SUBSTITUTED ADENOSINE DERIVATIVES, N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2012-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10174033-B2 | N6-substituted adenosine derivatives and N6-substituted adenine derivatives and uses thereof | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885PI4KA 847/4885PI4K2B 1111/4885 |
| US-20130045942-A1 | N6-SUBSTITUTED ADENOSINE DERIVATIVES AND N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885PI4KA 847/4885PI4K2B 1111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.